Bluebirdbio stock.

Item 1.01. Entry into a Material Definitive Agreement. On January 18, 2023, bluebird bio, Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as...Latest news about bluebird bio, Inc. Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating. Nov. 08. MT. Transcript : Bluebird bio, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M. Nov. 07.On average, Wall Street analysts predict. that Bluebird Bio's share price could reach $7.64 by Nov 8, 2024. The average Bluebird Bio stock price prediction forecasts a potential upside of 96.45% from the current BLUE share price of $3.89.To say that biotech Bluebird Bio (BLUE 12.50%) has significantly lagged the market in the past year would be an understatement. ... Why Bluebird Bio Stock Soared 7% Higher on Tuesday.SOMERVILLE, Mass.--(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its …

Nov 28, 2022 · bluebird bio has received approval for their first products and are on track to treat their first patient later this year. Find out why BLUE stock is a hold. View the latest bluebird bio Inc. (BLUE) stock price, news, historical charts, analyst ratings and financial information from WSJ.bluebird bio, Inc. Common Stock (BLUE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Trading bluebird bio to $6: Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in prBluebird bio (BLUE ...Aug 28, 2023 · Bluebird Bio (BLUE 11.52%), a leader in gene therapy, could be a great pick for growth investors.This company has two gene therapies that the U.S. Food and Drug Administration (FDA) has approved ...

One particular, let's check out Bluebird. Shares of Bluebird Bio, ticker symbol BLUE, now, you're seeing that move lower by about 11.3%. This is after the Food and Drug Administration approved the ...It takes a lot of money to launch gene therapies, and CRISPR has a much bigger war chest than Bluebird Bio. As of Sept. 30, the company had $1.973 billion in cash while Bluebird, even after ...As bluebird bio launches two first-in-class gene therapies and readies its third investigational gene therapy for SCD for the commercial setting, full-year 2023 cash burn is expected to be in the ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …

Zolmax • 12 days ago. Track Bluebird bio Inc (BLUE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get …

View the latest bluebird bio Inc. (BLUE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases.AnaptysBio Inc. 14.20. UNCH. UNCH. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. bluebird bio, Inc. Common Stock (BLUE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ... Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Bluebird Bio’s Weak Cash Position. Bluebird Bio’s stock trades a whopping 98% below its March 2018 peak and has lost 80% of its value since going public in June 2013. The company was ...

Real time Bluebird Bio (BLUE) stock price quote, stock graph, news & analysis.Bluebird Bio (BLUE 11.52%) is one of those companies, and it's hoping that an existing U.S. Food and Drug Administration (FDA) ... Why Bluebird Bio Stock Soared 7% Higher on Tuesday.Discover historical prices for BLUE stock on Yahoo Finance. View daily, weekly or monthly format back to when bluebird bio, Inc. stock was issued. bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share price if it lands this historic approval.Jul 12, 2023 · Curious what investors think of the latest price action? When the Bank of America upgraded its rating for Bluebird, the stock shot up from $3.13 to a high of $3.93, and today it closed at $3.51.

The bluebird bio stock price gained 3.74% on the last trading day (Thursday, 2nd Nov 2023), rising from $2.94 to $3.05. During the last trading day the stock fluctuated 7.02% from a day low at $2.92 to a day high of $3.13. The price has risen in 7 of the last 10 days and is up by 9.71% over the past 2 weeks. Volume has increased on the …bluebird bio specializes in gene therapies for severe genetic diseases and has 2 FDA-approved products. EV/Sales multiple appears cheap. Find out why BLUE stock is a Buy.

Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. bluebird bio, Inc. Common Stock (BLUE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market …Feb 24, 2023 · The market expects Bluebird Bio (BLUE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known consensus ... Jun 29, 2023 · Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ... Another factor that may be contributing to BLUE stock gaining ground today — which jumped 17% and is up nearly 22% at time of writing — centers on possible short-squeeze speculation. According ...10 thg 3, 2021 ... BLUE Stock Pops On Gene Therapy Analysis ... On the stock market today, BLUE stock jumped 8.1% to 32.48. Bluebird uses an empty virus to deliver ...bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency.bluebird bio, Inc. BLUE Bluebird Bio signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release. The company’s stock has a 52-week low of $2.78.The current price bluebird bio (BLUE) is trading at is $3.87, which is out of the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular Channels

bluebird bio Inc. Watch NEW Set a price target alert Open Last Updated: Nov 27, 2023 1:11 p.m. EST Real time quote $ 3.7650 -0.1250 -3.21% Previous Close $3.8900 Advanced Charting Volume: 2.77M...

bluebird bio, Inc. BLUE Bluebird Bio signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release. The company’s stock has a 52-week low of $2.78.

Target values for the price of one bluebird bio share for Nov 2025. The weighted average target price per bluebird bio share in Nov 2025 is: 8.72. In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 19.746% volatility is expected. Pessimistic target level: 7.95. Optimistic target level: 9.91.bluebird bio, Inc. (BLUE) Stock Price, Quote, News & Analysis Black Friday is here! Get Premium + Alpha Picks for ONLY $438 $239 » BLUE bluebird bio, Inc. …Bitcoin CAD 51,654.22 +442.98(+0.87%) bluebird bio, Inc. (BLUE) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist 3.7900 +0.1300 (+3.55%) At close: …If you're looking for growth stocks that are at the spear's tip of innovation, you might want to check out Bluebird Bio (BLUE 11.52%) and Arista Networks (ANET-1.40%).Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next 30-90 days. Recent stocks from this report have soared up to +178.7% in 3 months - this month ...Dec 20, 2021 · Shares of Bluebird Bio ( BLUE -3.00%) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its ... May 21, 2020 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to ... Find the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.As for liquidity, bluebird bio reported ~$227M in cash, cash equivalents, marketable securities, and restricted cash as of 2022 year-end and indicated a cash runway until Q4 2024, including ~$45M ...12 thg 7, 2023 ... Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows. ... bluebird bio's product pipeline (www.Who is on bluebird bio's Insider Roster? The list of insiders at bluebird bio includes Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima, and William D Baird III. Learn more on insiders at BLUE.

Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ...bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases.Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Instagram:https://instagram. loan companies for bankruptciesumicore sacrypto tracker appnuscale power stock price SCD (HGB-206) bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established. View the bluebird bio development pipeline and explore our list of gene therapy products and candidates at all development phases. best option strategymilitary lost a jet In the second quarter, it reported revenue of just $6.9 million, an improvement over the $1.5 million recorded in the year-ago period. Bluebird was also unprofitable, with a net loss of $0.67 per ... precision biosciences inc stock Latest news about bluebird bio, Inc. Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating. Nov. 08. MT. Transcript : Bluebird bio, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M. Nov. 07.Dec 1, 2023 · Shares of bluebird bio BLUE have increased by 25.6% in a month compared with the industry ’s growth of 0.2%. Last month, bluebird posted better-than-expected results in the third quarter. It ...